文献速递神经肿瘤

190例原发性非典型脑膜瘤的无进展生存与复发预后因素

Progressing-Free Survival and Prognostic Factors With Recurrence in 190 Patients With Primary Atypical Meningiomas.
PubMed 文献 · World Neurosurg · 2025-11-19

回顾性纳入190例2013年9月至2023年7月接受手术的原发性非典型脑膜瘤患者,中位无进展生存期40.4个月,40例(21.1%)复发。多因素Cox分析显示肿瘤大小、切除程度和颅底位置是复发的独立预测因素,术后放疗未显著延长无进展生存期(P=0.332)。

要点

  • 肿瘤大小、Simpson切除分级和颅底位置是非典型脑膜瘤复发的独立预测因素。
  • 术后放疗未显著降低非典型脑膜瘤复发风险(P=0.332)。
  • Simpson I-II级切除占84.2%,中位无进展生存期40.4个月。

核心结论

  • 肿瘤大小、切除程度和颅底位置是非典型脑膜瘤复发的强预测因素。
  • 术后放疗可能不降低非典型脑膜瘤患者的复发风险。

研究设计与样本

  • 回顾性纳入190例2013年9月至2023年7月接受手术的原发性非典型脑膜瘤患者。
  • 分析手术切除程度、肿瘤位置、脑侵犯、骨侵犯及放疗与否等因素,采用单因素和多因素分析评估复发相关预后因素。

主要发现

  • 中位无进展生存期为40.4个月(范围6-108个月),Simpson I-II级切除160例(84.2%),术后放疗22例(11.6%)。
  • 中位肿瘤大小4.92 cm(范围1.6-9.8 cm),肿瘤≥5.0 cm者94例,颅底位置48例(25.3%)。
  • 随访期间40例(21.1%)复发。
  • 多因素Cox分析:肿瘤大小(HR=2.292;P=0.013)、切除程度(Simpson I-II vs III-IV,HR=4.112;P<0.001)、颅底位置(HR=2.071;P=0.032)为独立预测因素。
  • 放疗组复发率18.2%(4/22),未放疗组21.4%(36/168),术后放疗与更长无进展生存期无显著关联(P=0.332)。

临床怎么用

  • 对肿瘤较大、颅底位置或Simpson III-IV级切除的非典型脑膜瘤患者应加强术后复发监测。
  • 术后放疗在非典型脑膜瘤中的获益未在本研究中证实,需个体化决策。

局限性

  • 回顾性研究设计。
  • 样本量有限,放疗组仅22例。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For atypical meningioma (AM), there is a high postoperative local recurrence rate. Although adjuvant radiotherapy has been practiced in patients with AM resection, its role remains controversial. In this study, progression-free survival (PFS) of AM patients was analyzed, and factors associated with postoperative recurrence were identified. METHODS: A total of 190 AM patients who visited our institutions and had surgery between September 2013 and July 2023 were retrospectively included in this study. Factors such as the extent of surgical resection, tumor location, brain invasion, bone invasion, and therapy modality (if radiotherapy was used or not) were analyzed. Recurrence-related prognostic factors were assessed with univariate and multivariate analyses. RESULT: The median PFS was 40.4 months (range: 6-108 months), Simpson grade I-II resection was achieved in 160 (84.2%) patients, and 22 (11.6%) patients received postoperative radiotherapy (RT). The median tumor size was 4.92 cm (range: 1.6-9.8 cm) and tumor size measured to be ≥ 5.0 cm in 94 patients. The tumor was located at the skull base for 48 patients (25.3%). During follow-up, tumor recurrence was observed in 40 (21.1%) patients. Multivariate Cox analysis showed that tumor size (hazard ratio = 2.292; P = 0.013), extent of resection (Simpson grade I-II vs. Simpson grade III-IV, hazard ratio = 4.112; P < 0.001), and skull base location (hazard ratio = 2.071; P = 0.032) were significant and independent predictors of tumor recurrence. The rate of tumor recurrence was 18.2% (4 of 22) for patients who received RT, and 21.4% (36 of 168) for patients did not receive RT. No significant association between longer PFS and postoperative radiotherapy was found, regardless the degree of resection (P = 0.332). CONCLUSIONS: Tumor size, extent of resection, and skull base location were powerful predictors for recurrence in AM patients. The risk of recurrence in AM patients might not be decreased by postoperative RT. Future studies on larger cohorts including AM patients combining advanced RT and chemotherapy are still needed.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Sun W, Zhang Y, Wu X, et al. Progressing-Free Survival and Prognostic Factors With Recurrence in 190 Patients With Primary Atypical Meningiomas. World Neurosurg. 2025. PMID: 41265785. doi:10.1016/j.wneu.2025.124646

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。